Abstract 1953P
Background
The diversity of clinical and pathological characteristics of soft tissue sarcoma (STS) presents a challenge for the prediction of prognosis. Recently, pretreatment inflammatory markers have gained interest as predictive factors for survival in cancer patients. The aim of this study is to evaluate inflammatory markers as a predictive biomarker for early recurrence in STS.
Methods
118 patients with primary, localized soft tissue sarcoma were retrospectively reviewed for early recurrence. Early recurrence was defined as a disease relapse (local or distant) within the first year after diagnosis. Pretreatment inflammatory markers including leukocytes, interleukin-6 (IL-6), C-reactive protein (CRP), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and other variables including tumor grade, tumor Departmenth, location, size, and the presence of tumor necrosis on imaging were analyzed for their association with early recurrence. Survival data was analyzed using Log-rank test and Cox regression to identify prognostic factors for early recurrence.
Results
Pretreatment IL-6 elevation was associated with higher tumor grade, increased size, and necrosis on imaging. Elevated CRP was associated with higher tumor grade, NLR and PLR with tumor Departmenth, and PLR with tumor location. Early recurrences were found in 23 of 118 patients (19.5%): 7 local, 15 distant recurrences and 1 with both manifestations. Univariate analysis revealed that tumor grade (low vs high, p = 0.008), tumor Departmenth (superficial vs deep, p = 0.005), and IL-6 level (< 7 vs ≥ 7 ng/L, p = 0.012) were significantly associated with early recurrence; other inflammatory markers including leukocytes, CRP, NLR and PLR were not. Multivariate analysis did not reveal independent risk factors associated with the development of early recurrences in STS, although the number of cases were low.
Conclusions
Early recurrences in STS are not only associated with higher grade and deeper tumors, but also with increased plasma levels of IL-6.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
W.T.A. Van Der Graaf: Financial Interests, Institutional, Advisory Board: PTC Therapeutics, Agenus, SpringworksTx; Financial Interests, Institutional, Local PI, Clinical study: Springworks, Boehringer Ingelheim; Financial Interests, Institutional, Research Grant, IIS: Lilly; Financial Interests, Institutional, Local PI, Clinical Study: AYALA; Non-Financial Interests, Member of Board of Directors, President: EORTC; Non-Financial Interests, Member of Board of Directors: European Cancer Organisation; Non-Financial Interests, Member of Board of Directors, Chair: Dutch Sarcoma Group, Dutch AYA 'Young and Cancer' Care Network. D. Van Den Broek: Financial Interests, Institutional, Advisory Board: Roche; Financial Interests, Institutional, Expert Testimony: Roche; Financial Interests, Institutional, Invited Speaker: Roche; Financial Interests, Institutional, Research Funding: ZonMW, Delfi Diagnostics. N. Steeghs: Financial Interests, Institutional, Advisory Board: Boehringer Ingelheim, Ellipses Pharma, Luszana; Financial Interests, Personal, Advisory Board: GSK, Incyte; Financial Interests, Institutional, Local PI: AbbVie, Actuate Therapeutics, Amgen, Array, Ascendis Pharma, AstraZeneca, Bayer, Blueprint Medicines, Boehringer Ingelheim, BridgeBio, BMS, Cantargia, CellCentric, Cogent Biosciences, Crescendo Biologics, Cytovation, Deciphera, Dragonfly, Eli Lilly, Exelixis, Genentech, GSK, IDRx, Immunocore, Incyte, InteRNA, Janssen, Kinnate Biopharma, Kling Biotherapeutics, Luszana, Merck, Merck Sharp & Dohme, Merus, Molecular Partners, Navire Pharma, Novartis, Numab Therapeutics, Pfizer, Relay Pharmaceuticals, Revolution Medicin, Roche, Sanofi, Seattle Genetics, Taiho, Takeda; Financial Interests, Institutional, Research Grant: AstraZeneca, Bayer, Deciphera, GSK, Lixte, Merck, Novartis, Pfizer, Roche. W. Van Houdt: Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Advisory Board: Belpharma, Sanofi, MSD; Financial Interests, Personal, Other, travel grant: Novartis; Financial Interests, Institutional, Local PI: BMS. All other authors have declared no conflicts of interest.
Resources from the same session
1982P - Transcriptomic analysis and tumor microenvironment (TME) classification reveals unique immune biology in HIV patients with Kaposi sarcoma (KS)
Presenter: Jihua Yang
Session: Poster session 15
1983P - Palliative spatially fractionated stereotactic radiation therapy (Lattice) for large sarcoma
Presenter: Gabriela Studer
Session: Poster session 15
1984P - Sex differences in anticancer treatment delivery and toxicity in patients with sarcoma in a reference center
Presenter: Ilaria Tortorelli
Session: Poster session 15
1985P - Expert sarcoma care is the need of the hour: Diagnostic and management challenges at a tertiary-care centre in India
Presenter: Ghazal Tansir
Session: Poster session 15
1986P - Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: An analysis from the OnCovid registry
Presenter: Alessandro Mazzocca
Session: Poster session 15
1987TiP - Pembrolizumab in combination with eftilagimod alpha and radiotherapy in neoadjuvant treatment of patients with soft tissue sarcomas: EFTISARC-NEO trial
Presenter: Katarzyna Kozak
Session: Poster session 15
2213P - Impact of the diagnosis-to-treatment interval on the survival of patients with papillary thyroid cancer
Presenter: Tingting Wei
Session: Poster session 15
2214P - Identification of prognosis-associated genes in locally advanced well-differentiated thyroid cancer using TCGA cohort analysis
Presenter: Ah Ra Jung
Session: Poster session 15
2216P - Clinicopathologic and genetic characteristics of patients of different ages with diffuse sclerosing variant papillary thyroid carcinoma
Presenter: Soo Young Kim
Session: Poster session 15
2220P - MOLTHY project (TTCC-2020-02): A Spanish observational study for MOLecular characterization of THYroid carcinoma
Presenter: Neus Baste Rotllan
Session: Poster session 15